Therapeutic Antibody Discovery
Screen and manage antibody sequence data in the cloud.
The power behind precision antibody discovery
Significantly speed up candidate selection by leveraging vast datasets, including NGS outputs
Visualize results with a user friendly interface and purpose-built pipelines that optimize the antibody screening process
Transform data management and increase process efficiency with data consolidated in a secure and shareable cloud environment
Scalable IT infrastructure with access to a whole team of bioinformaticians, scientists and IT
“Often, you have to shoehorn a software solution into your process; the adaptability of Geneious Biologics was something we liked a lot. Once we knew what we could do with Geneious Biologics, there was no other viable option.”
– Liuhong Chen, Ph.D. Discovery Biology Team Leader at Bicycle Therapeutics
A better system for sequence data
Stop relying on piecemeal systems that routinely break. Geneious Biologics consolidates data in a secure and shareable cloud environment, speeding up candidate selection and ensuring reproducibility.
Precise tools to speed up development
Struggling with suboptimal processes? Geneious Biologics comes with purpose-built pipelines that have been created specifically for optimizing the antibody screening process. Start visualizing results using a specialized and user-friendly interface.
Get the most from next generation sequencing
Generating more high-throughput data should not be a barrier. Geneious Biologics equips you with the ability to filter and group sequences according to your specific requirements creating more opportunities to find the next star candidate.
Access to a team of bioinformaticians, scientists and IT
Don’t spend a fortune on your infrastructure. The Geneious team is made up of highly qualified and skilled people who want to help you get the most out of your data. Tools are regularly updated and optimized, and support scientists are readily available to assist you.
“Geneious Biologics allows us to drill into huge antibody sequence sets and quickly identify where errors lie and inspect bad clones. This will ensure we return the most effective, stable therapeutic antibody candidates to our clients, faster.”
– Daniela Teixeira, COO at FairJourney Biologics